[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eikon Therapeutics Inc (EIKN)

Eikon Therapeutics Inc (EIKN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 481,837
  • Shares Outstanding, K 54,139
  • Annual Sales, $ 0 K
  • Annual Income, $ -324,250 K
  • EBIT $ -159 M
  • EBITDA $ -135 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.61
  • Number of Estimates 4
  • High Estimate $-1.48
  • Low Estimate $-1.69
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.72 +2.06%
on 07/24/26
13.54 -34.27%
on 06/30/26
-0.73 (-7.58%)
since 06/24/26
3-Month
7.90 +12.66%
on 04/28/26
13.54 -34.27%
on 06/30/26
-0.76 (-7.82%)
since 04/24/26

Most Recent Stories

More News
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Presentations to cover updates across Eikon’s clinical pipeline including:  Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and...

EIKN : 8.90 (-7.48%)
Eikon Therapeutics to Join the Russell 3000® Index

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines...

EIKN : 8.90 (-7.48%)
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines...

EIKN : 8.90 (-7.48%)
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control,...

EIKN : 8.90 (-7.48%)
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

Presentations to cover progress across Eikon’s most advanced clinical-stage programs Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell...

EIKN : 8.90 (-7.48%)
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026 Continued execution across the oncology pipeline, with a strategic focus...

EIKN : 8.90 (-7.48%)
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small...

EIKN : 8.90 (-7.48%)
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering

MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to...

EIKN : 8.90 (-7.48%)

Key Turning Points

3rd Resistance Point 10.66
2nd Resistance Point 10.24
1st Resistance Point 9.57
Last Price 8.90
1st Support Level 8.48
2nd Support Level 8.05
3rd Support Level 7.38

See More

52-Week High 17.40
Fibonacci 61.8% 13.77
Fibonacci 50% 12.65
Fibonacci 38.2% 11.53
Last Price 8.90
52-Week Low 7.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.